Login
$IONS
$28.02 +$0.01 (0.04%) After hours

$IONS 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

– ZANVASTROTM (zilganersen) first approved medicine for Alexander disease; first independent launch underway from leading neurology pipeline –

23 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

21 Oct 2026 8-K: Regulation FD Disclosure; Other Events

– Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care –

23 Sep 2026 8-K: Regulation FD Disclosure; Other Events

– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –

04 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

04 Sep 2026 8-K: Regulation FD Disclosure; Other Events

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

29 Jul 2026 8-K: Results of Operations and Financial Condition

- TRYNGOLZA® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population –

10 Jul 2026 8-K: Regulation FD Disclosure

Ionis Pharmaceuticals, Inc. (the “Company”) is reaffirming its previously announced financial guidance for the fiscal year ending December 31, 2026, which remains unchanged from the financial guidance the Company provided on April 29, 20...

09 Jul 2026 8-K: Regulation FD Disclosure; Other Events

– Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with eplontersen monotherapy –

24 Jun 2026 8-K: Regulation FD Disclosure; Other Events

TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

12 Jun 2026 8-K: Other Events

On June 12, 2026, Ionis Pharmaceuticals, Inc. (“Ionis”) shared positive new data from the open-label extension study of CORE and CORE2 (“CORE-OLE”) evaluating olezarsen in people with severe hypertriglyceridemia (“sHTG”) during an oral p...

08 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more

CARLSBAD, Calif., June 8, 2026 -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective immediately.

28 May 2026 8-K: Regulation FD Disclosure; Other Events

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

29 Apr 2026 8-K: Results of Operations and Financial Condition

- TRYNGOLZA® (olezarsen) showed increasing demand in FCS driven by strong launch execution –

21 Apr 2026 8-K: Regulation FD Disclosure; Other Events

CARLSBAD, Calif., April 21, 2026 -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progress...

09 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

CARLSBAD, Calif., March 9, 2026 -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will be retiring at the end of their term and Peter ...

25 Feb 2026 8-K: Results of Operations and Financial Condition

- TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch –

12 Jan 2026 8-K: Results of Operations and Financial Condition

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

07 Jan 2026 8-K: Regulation FD Disclosure; Other Events

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

17 Nov 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

INDENTURE dated as of November 17, 2025 between IONIS PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support